Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo

Although sorafenib, an oral multikinase inhibitor, was approved as a treatment drug of advance hepatocellular carcinoma (HCC), treatment efficacy still requires improvement. Searching for the adjuvant reagent for enhancing sorafenib efficacy remains as a critical issue. Sorafenib has been proved to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiann-Hwa, Chiang, I-Tsang, Hsu, Fei-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017147/
https://www.ncbi.nlm.nih.gov/pubmed/31905887
http://dx.doi.org/10.3390/cancers12010087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017147/
https://www.ncbi.nlm.nih.gov/pubmed/31905887
http://dx.doi.org/10.3390/cancers12010087

Ejemplares similares